Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Current Leases (2019 - 2025)

Spero Therapeutics (SPRO) has disclosed Current Leases for 7 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases rose 9.2% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Sep 2025, up 9.2%, and an annual FY2024 reading of $1.7 million, up 1.63% over the prior year.
  • Current Leases was $1.9 million for Q3 2025 at Spero Therapeutics, up from $1.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.9 million in Q3 2025 and bottomed at $980000.0 in Q1 2021.
  • Average Current Leases over 5 years is $1.6 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Current Leases plummeted 31.72% in 2021, then surged 61.52% in 2022.
  • Year by year, Current Leases stood at $1.4 million in 2021, then rose by 24.08% to $1.7 million in 2022, then grew by 1.66% to $1.7 million in 2023, then rose by 1.63% to $1.7 million in 2024, then increased by 8.76% to $1.9 million in 2025.
  • Business Quant data shows Current Leases for SPRO at $1.9 million in Q3 2025, $1.8 million in Q2 2025, and $1.8 million in Q1 2025.